-
- TRL (Technology readiness level) -
-
- Titre New biodegradable anti-migration intestinal stent
- Description In the US, nearly 1,5 million patients suffer from Crohn’s disease. The most common complication is digestive stenosis (50% of patients).
If the stenosis measures less than 5 centimeters, an endoscopic dilatation is possible. However, it is associated with relapse rates of 30 to 50 % at 1-3 years. In this case, the patient undergoes another endoscopic dilatation or sometimes a bowel resection. The use of covered expandable metallic prostheses (used for malignant obstructions) could enhance the long-term efficacy of endoscopic dilatation. However, this solution is currently not possible, due to a high rate of uncontrolled migration (30 to 80% of cases).
Our solution is a new stent with an original anti-migration design.
- Bénéfices The anti-migration stent allows to treat patients with short benign stenosis (Crohn’s diseases, post-operative colonic stenosis…) with a zero rate of migration (validated with metallic stent). A biodegradable version of this stent would allow a significant reduction in the risk associated with device removal (to be validated). The progressive and spontaneous disintegration of the biodegradable stent takes a few weeks and avoids the need for a second extraction colonoscopy and its complications.
- Nouveauté New anti-migration design.
Biodegradable.
- Mots clés Digestive diseases, Stenosis, Cancer, Crohn’s disease, Stricture, Stent, Anti-migration system
- Secteurs Health
